Kancera AB (publ) (KAN.ST)
SEK 1.13
(9.51%)
SEK 1.13
(9.51%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -61.88 Million SEK | -21.29% |
| 2022 | -52 Million SEK | -14.68% |
| 2021 | -45.34 Million SEK | 4.25% |
| 2020 | -44.76 Million SEK | -32.41% |
| 2019 | -33.4 Million SEK | 21.64% |
| 2018 | -45.41 Million SEK | 17.25% |
| 2017 | -55.03 Million SEK | -160.57% |
| 2016 | -21.16 Million SEK | -14.3% |
| 2015 | -18.52 Million SEK | -23.86% |
| 2014 | -14.95 Million SEK | -123.41% |
| 2013 | -6.69 Million SEK | 74.56% |
| 2012 | -26.31 Million SEK | -3.79% |
| 2011 | -14.31 Million SEK | -253.71% |
| 2010 | -7.16 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -11.35 Million SEK | 15.86% |
| 2024 Q1 | -13.39 Million SEK | 22.28% |
| 2023 Q3 | -10.42 Million SEK | 41.68% |
| 2023 Q4 | -19.42 Million SEK | -86.3% |
| 2023 FY | - SEK | -21.29% |
| 2023 Q2 | -17.88 Million SEK | -4.59% |
| 2023 Q1 | -17.09 Million SEK | -19.43% |
| 2022 Q4 | -14.31 Million SEK | -34.6% |
| 2022 Q3 | -10.63 Million SEK | 30.38% |
| 2022 Q1 | -11.78 Million SEK | 10.03% |
| 2022 Q2 | -15.27 Million SEK | -29.66% |
| 2022 FY | - SEK | -14.68% |
| 2021 Q4 | -13.09 Million SEK | -21.21% |
| 2021 FY | - SEK | 4.25% |
| 2021 Q1 | -8.91 Million SEK | 30.02% |
| 2021 Q2 | -18.15 Million SEK | -103.66% |
| 2021 Q3 | -10.8 Million SEK | 40.48% |
| 2020 Q2 | -13.88 Million SEK | -31.58% |
| 2020 FY | - SEK | -32.41% |
| 2020 Q3 | -8.89 Million SEK | 35.97% |
| 2020 Q4 | -12.73 Million SEK | -43.22% |
| 2020 Q1 | -10.55 Million SEK | -39.84% |
| 2019 Q1 | -7.86 Million SEK | 36.06% |
| 2019 FY | - SEK | 21.64% |
| 2019 Q4 | -7.54 Million SEK | -1.42% |
| 2019 Q3 | -7.44 Million SEK | 41.33% |
| 2019 Q2 | -12.68 Million SEK | -61.24% |
| 2018 Q4 | -12.3 Million SEK | -15.83% |
| 2018 FY | - SEK | 17.25% |
| 2018 Q3 | -10.62 Million SEK | -6.34% |
| 2018 Q2 | -9.98 Million SEK | 18.32% |
| 2018 Q1 | -12.22 Million SEK | -4.69% |
| 2017 FY | - SEK | -160.57% |
| 2017 Q2 | -17.67 Million SEK | -88.08% |
| 2017 Q1 | -9.39 Million SEK | -51.0% |
| 2017 Q3 | -16.27 Million SEK | 7.93% |
| 2017 Q4 | -11.68 Million SEK | 28.22% |
| 2016 Q3 | -4.96 Million SEK | 4.55% |
| 2016 Q1 | -4.75 Million SEK | 15.24% |
| 2016 FY | - SEK | -14.3% |
| 2016 Q4 | -6.22 Million SEK | -25.31% |
| 2016 Q2 | -5.2 Million SEK | -9.53% |
| 2015 Q4 | -5.6 Million SEK | -85.41% |
| 2015 FY | - SEK | -23.86% |
| 2015 Q1 | -4.68 Million SEK | 3.5% |
| 2015 Q3 | -3.02 Million SEK | 42.02% |
| 2015 Q2 | -5.21 Million SEK | -11.39% |
| 2014 Q2 | -3.49 Million SEK | 9.89% |
| 2014 Q4 | -4.85 Million SEK | -77.11% |
| 2014 FY | - SEK | -123.41% |
| 2014 Q3 | -2.73 Million SEK | 21.54% |
| 2014 Q1 | -3.87 Million SEK | -133.94% |
| 2013 Q4 | -1.65 Million SEK | 36.6% |
| 2013 Q3 | -2.61 Million SEK | 20.22% |
| 2013 Q2 | -3.27 Million SEK | -41.67% |
| 2013 FY | - SEK | 74.56% |
| 2013 Q1 | -2.31 Million SEK | 60.74% |
| 2012 Q3 | -6.34 Million SEK | 26.24% |
| 2012 Q1 | -7.01 Million SEK | 42.36% |
| 2012 Q4 | -5.88 Million SEK | 7.2% |
| 2012 FY | - SEK | -3.79% |
| 2012 Q2 | -8.59 Million SEK | -22.51% |
| 2011 Q1 | 1.74 Million SEK | 131.04% |
| 2011 Q2 | -7.48 Million SEK | -528.68% |
| 2011 Q3 | -4.47 Million SEK | 40.31% |
| 2011 Q4 | -12.17 Million SEK | -172.44% |
| 2011 FY | - SEK | -253.71% |
| 2010 Q4 | -5.62 Million SEK | -578.89% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q3 | -829 Thousand SEK | -16.6% |
| 2010 Q2 | -711 Thousand SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Active Biotech AB (publ) | -43.88 Million SEK | -41.019% |
| Amniotics AB (publ) | -27.14 Million SEK | -128.011% |
| BioArctic AB (publ) | 275.38 Million SEK | 122.473% |
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 83.173% |
| Camurus AB (publ) | 562.54 Million SEK | 111.002% |
| Cantargia AB (publ) | -284.31 Million SEK | 78.232% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -216.099% |
| CombiGene AB (publ) | -35.33 Million SEK | -75.144% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 56.061% |
| Genovis AB (publ.) | 64.57 Million SEK | 195.845% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 46.14% |
| Mendus AB (publ) | -97.84 Million SEK | 36.749% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -67.159% |
| Intervacc AB (publ) | -68.98 Million SEK | 10.28% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -131.076% |
| LIDDS AB (publ) | -39.67 Million SEK | -56.01% |
| Lipum AB (publ) | -37.11 Million SEK | -66.731% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -411.31% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 297.074% |
| NextCell Pharma AB | -40.98 Million SEK | -51.003% |
| OncoZenge AB (publ) | 7.26 Million SEK | 951.762% |
| Saniona AB (publ) | -69.69 Million SEK | 11.2% |
| Simris Alg AB (publ) | -22.36 Million SEK | -176.747% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 80.505% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 78.056% |
| Xintela AB (publ) | -53.47 Million SEK | -15.743% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 63.555% |
| Ziccum AB (publ) | -20.34 Million SEK | -204.242% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -335.317% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -262.252% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 3094550.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 73.954% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -2875.433% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -360.792% |
| Corline Biomedical AB | -1.69 Million SEK | -3559.905% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 64.293% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -12.924% |
| Aptahem AB (publ) | -10 Million SEK | -518.319% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 635.882% |
| Fluicell AB (publ) | -25.91 Million SEK | -138.825% |
| Biovica International AB (publ) | -119.5 Million SEK | 48.213% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -46.573% |
| AcouSort AB (publ) | -16.7 Million SEK | -270.526% |
| Abliva AB (publ) | -93.6 Million SEK | 33.885% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 80.605% |
| 2cureX AB (publ) | -35.13 Million SEK | -76.141% |
| I-Tech AB | 30.34 Million SEK | 303.951% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 91.339% |
| Cyxone AB (publ) | -20.41 Million SEK | -203.169% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 39.593% |
| Biosergen AB | 228 Thousand SEK | 27244.298% |
| Nanologica AB (publ) | -62.11 Million SEK | 0.37% |
| SynAct Pharma AB | -222.7 Million SEK | 72.21% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -41.103% |
| BioInvent International AB (publ) | -312.7 Million SEK | 80.209% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 20102.068% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 147458.27% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 73.28% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -602.288% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 42.99% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -439.62% |